Short Interest in Insys Therapeutics Rises By 51.6% (INSY)
Shares of Insys Therapeutics (NASDAQ:INSY) were the target of a large increase in short interest in the month of May. As of May 30th, there was short interest totalling 5,179,897 shares, an increase of 51.6% from the May 15th total of 3,416,044 shares, American Banking & Market News reports. Based on an average trading volume of 689,164 shares, the short-interest ratio is currently 7.5 days. Currently, 51.9% of the shares of the company are short sold.
Insys Therapeutics (NASDAQ:INSY) opened at 25.03 on Friday. Insys Therapeutics has a one year low of $7.1467 and a one year high of $57.9133. The stock has a 50-day moving average of $30.54 and a 200-day moving average of $35.12. The company has a market cap of $856.8 million and a P/E ratio of 17.36.
Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.23 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.28 by $0.05. The company had revenue of $41.60 million for the quarter, compared to the consensus estimate of $45.63 million. During the same quarter last year, the company posted $0.01 earnings per share. Insys Therapeutics’s revenue was up 274.8% compared to the same quarter last year. On average, analysts predict that Insys Therapeutics will post $1.15 earnings per share for the current fiscal year.
Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.